Editas Medicine to Participate in Upcoming Investor Conferences
Get Alerts EDIT Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel:
- Morgan Stanley 22nd Annual Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 4
Time: 4:05 p.m. ET
Location: New York, NY
- 2024 Wells Fargo Healthcare Conference
Format: Fireside Chat
Date: Thursday, September 5
Time: 4:30 p.m. ET
Location: Boston, MA
- 2024 Cantor Global Healthcare Conference
Format: Fireside Chat
Date: Tuesday, September 17
Time: 1:20 p.m. ET
Location: New York, NY
- Chardan 8th Annual Genetic Medicines Conference
Format: Fireside Chat
Date: Tuesday, October 1
Time: 4:00 p.m. ET
Location: New York, NY
To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.
About Editas Medicine
As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
- CorelDRAW 2026 Review: New Features and Workflow Updates for Designers and Print Professionals Highlighted by Expert Consumers
- 5 Top Meme Coins Before September: Could Apeing’s Upcoming Crypto Presale Make the Biggest Splash in the Meme Coin Market?
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Morgan Stanley, Wells Fargo, Chardan Capital MarketsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share